Malignant Hyperthermia Syndrome : A Clinical Case Report
Copyright © 2021 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved..
Malignant hyperthermia is a pharmacogenetic disorder. It manifests as a hypercatabolic skeletal muscle syndrome linked to inhaled volatile anesthetics or depolarizing muscle relaxants. Its clinical signs and symptoms are tachycardia, hyperthermia, hypercapnia, acidosis, muscle rigidity, rhabdomyolysis, hyperkalemia, arrhythmia and renal failure. Mortality without specific treatment is 80% and decreases to 5% with the use of dantrolene sodium. This article presents the case of a 39-year-old patient admitted to the Intensive Care Unit for malignant hyperthermia after surgery for septoplasty plus turbinoplasty.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
EJIFCC - 32(2021), 2 vom: 23. Juni, Seite 286-291 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Acosta, Isabel Sánchez-Molina [VerfasserIn] |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 07.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM32964856X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32964856X | ||
| 003 | DE-627 | ||
| 005 | 20231225205553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM32964856X | ||
| 035 | |a (NLM)34421497 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Acosta, Isabel Sánchez-Molina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Malignant Hyperthermia Syndrome |b A Clinical Case Report |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved. | ||
| 520 | |a Malignant hyperthermia is a pharmacogenetic disorder. It manifests as a hypercatabolic skeletal muscle syndrome linked to inhaled volatile anesthetics or depolarizing muscle relaxants. Its clinical signs and symptoms are tachycardia, hyperthermia, hypercapnia, acidosis, muscle rigidity, rhabdomyolysis, hyperkalemia, arrhythmia and renal failure. Mortality without specific treatment is 80% and decreases to 5% with the use of dantrolene sodium. This article presents the case of a 39-year-old patient admitted to the Intensive Care Unit for malignant hyperthermia after surgery for septoplasty plus turbinoplasty | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a dantrolene | |
| 650 | 4 | |a desflurane | |
| 650 | 4 | |a inhaled anesthetics | |
| 650 | 4 | |a malignant hyperthermia | |
| 650 | 4 | |a ryanodine | |
| 650 | 4 | |a succinylcholine | |
| 700 | 1 | |a de Cos, Guillermo Velasco |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández, Matilde Toval |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EJIFCC |d 1999 |g 32(2021), 2 vom: 23. Juni, Seite 286-291 |w (DE-627)NLM264815653 |x 1650-3414 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:2 |g day:23 |g month:06 |g pages:286-291 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 2 |b 23 |c 06 |h 286-291 | ||